Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Fiche publication

Date publication

août 2026

Journal

Journal of neurology, neurosurgery, and psychiatry

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Zhu C, Vukusic S, Kalincik T, Mathey G, Kermode AG, Maillart E, Lechner-Scott J, Le Page E, Roos I, Ciron J, Kubala Havrdova E, Horakova D, De Sèze J, Skibina O, Ruet A, Yetkin MF, Labauge P, Habek M, Kwiatkowski A, Baghbanian SM, Zephir H, Meca-Lallana JE, Valero López G, Papeix C, Gerlach O, Defer G, Fabis-Pedrini M, Carroll WM, Lebrun-Frenay C, Hodgkinson S, Moreau T, Laureys G, Laplaud DA, Prat A, Berger E, Lapointe E, Clavelou P, Ampapa R, Thouvenot E, Stetkarova I, Heinzlef O, Stourac P, Pelletier J, Foschi M, Al Khedr A, D'Amico E, Casez O, Alroughani R, Bourre B, Brecl Jakob G, Creange A, Ozakbas S, David T, John N, Magy L, Camdessanché JP, Moulin S, Doghri I, Sarov Riviere M, Hankiewicz K, Pottier C, Manchon E, Aboab J, Tchikviladze M, Nifle C, Merlo D, Monif M, Zhou Z, Foong YC, Jokubaitis V, van der Walt A, Butzkueven H,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42601218

Résumé

Ofatumumab and ocrelizumab are widely used high-efficacy anti-CD20 therapies for relapsing-remitting multiple sclerosis (RRMS), but direct comparative evidence remains limited. We aimed to compare their effectiveness in routine clinical practice.